EMD Serono and Mersana Therapeutics entered an agreement to develop next-generation antibody-drug conjugates (ADCs) leveraging Mersana's Fleximer technology for multiple undisclosed targets. Both companies will test a variety of ADCs and several cytotoxic agents as conjugates.
EMD Serono will provide monoclonal antibodies and Mersana will generate the Fleximer-ADCs and conduct discovery and preclinical development activities. EMD Serono will be responsible for clinical development and commercialization of any resulting products under an exclusive license. Mersana will receive an upfront payment is eligible to receive milestones and royalties on worldwide sales.
"This new collaboration provides an exciting opportunity to expand our oncology drug discovery and development portfolio into the evolving ADC space," said Dr. Andree Blaukat, head of the Translational Innovation Platform Oncology at EMD Serono. "At EMD Serono, we have a long- standing commitment to improving oncology care, and we aim to deliver the best benefit possible to patients. Partnering with Mersana allows us to incorporate cutting-edge research and technical excellence to enrich our pipeline."
"We look forward to working with EMD Serono to apply our proprietary platform technologies to rapidly develop and demonstrate preclinical proof-of-concept of several customized, novel Fleximer-ADC candidates," said Timothy B. Lowinger, Ph.D., Mersana's chief scientific officer.